SSR 125047
Latest Information Update: 24 Feb 2009
At a glance
- Originator sanofi-aventis
- Class
- Mechanism of Action Sigma receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 31 Dec 2004 Discontinued - Phase-I for Schizophrenia in France (unspecified route)
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 11 Sep 2003 Phase-I clinical trials in Schizophrenia in France (unspecified route)